• Irfan Kabiruddin Jeeva, Sidra Masud, M A Rehman Siddiqui, and Hadees Murad Fahad.
• Dr. Irfan Kabiruddin Jeeva, FRCOphth (UK), FEBO (EU), CCT (UK), Department of Ophthalmology and Visual Sciences, Aga Khan University Hospital Karachi, Karachi, Pakistan.
• Pak J Med Sci. 2022 Nov 1; 38 (8): 232423302324-2330.

ObjectivesChorioretinal diseases requiring the use of anti-vascular endothelial growth (anti-VEGF) injections often occur in both eyes simultaneously. This can necessitate injecting both eyes together rather than one eye at a time. The purpose of the study was to determine whether simultaneous bilateral intravitreal injections of anti-VEGF agents are safe when administered in an operation theatre setting.MethodsRetrospective review of data was conducted. Single center study conducted in a tertiary care hospital in Karachi Pakistan. Approximately 30,000 eyes that received anti-VEGF injection during a 10-year study period were included (March 2008-February 2018). Patients who were lost to follow up prior to completion of treatment were excluded. Consecutive sampling technique was employed. The patients who received bilateral anti-VEGF injections were analysed separately from the ones who received unilateral injections. All injections were administered in operating theatre setting. The rate of endophthalmitis was measured in each group.ResultsA total of 30,258 injections were administered of which 15,338 were bilateral injections. Four cases (4/30,258, 0.013%) of endophthalmitis occurred during the study period. Only one case (1/15,338, 0.0065%) of endophthalmitis occurred after the administration of simultaneous bilateral anti-VEGF injections.ConclusionsAdministration of simultaneous bilateral anti-VEGF injections was safe in our population.Copyright: © Pakistan Journal of Medical Sciences.

0 keywords...

hide…